This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Metabolic Disease Program (WaVe/Pfizer)
WaVe Life Sciences Ltd.
Drug Names(s): Metabolic Disease Program (WaVe/Pfizer)
Description: WaVe and Pfizer are developing nucleic acid therapies for the treatment of various metabolic diseases. Initial targets include Apolipoprotein C-III (apoC-III), a protein synthesized in the liver that plays a central role in the regulation of serum triglycerides. It inhibits lipoprotein lipase and hepatic lipase, and an increase in apoC-III levels induces the development of hypertriglyceridemia.
WaVe and Pfizer
In May 2016, WAVE Life Sciences entered into a research, license and option agreement with Pfizer for the potential development of nucleic acid therapies aimed at silencing the underlying causes of debilitating metabolic diseases. The collaboration will focus on genetically defined targets and bring together WAVE's proprietary stereopure drug development platform, across antisense and RNAi modalities, along with GalNAc and Pfizers hepatic targeting technology for enhanced delivery to the liver.
Under the terms of the agreement, WAVE will advance up to five programs from discovery through to the selection of clinical candidates, at which point Pfizer may elect to exclusively license the programs and undertake further development and potential commercialization. Two targets have been declared upon initiation of the agreement, including WAVE's Apolipoprotein C-III program, with the remaining targets to be declared within eighteen months. In addition,...See full deal structure in Biomedtracker
Partners: Pfizer Inc.
Metabolic Disease Program (WaVe/Pfizer) News
Additional information available to subscribers only: